Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.

from News-Medical.Net Weight Loss News Feed http://ift.tt/1WPElGi
Follow Us on Twitter
Follow Us on FB
Follow Us on Pinterest
Follow Us on G+
Follow Us on Instagram
Follow Us on Instagram
Follow Us on Delicious
Follow Us on Wordpress